CalciMedica, Inc. filings document regulatory disclosures for a clinical-stage biopharmaceutical company developing CRAC channel inhibition therapies. The company’s Form 8-K reports cover results of operations and financial condition, clinical program events involving Auxora, and related updates for inflammatory and immunologic disease programs.
The filing record also includes capital-structure and governance disclosures, including Nasdaq continued-listing compliance matters, at-the-market offering documentation, shareholder voting matters, and the company’s common stock registration on The Nasdaq Capital Market under the symbol CALC.
CalciMedica Chief Medical Officer Sudarshan Hebbar received a stock option grant for 83,300 shares of common stock on June 24, 2025. The options were granted with an exercise price of $1.53 per share and are immediately exercisable with an expiration date of April 22, 2035.
Key details of the transaction:
- The option grant was initially approved by the Board on April 23, 2025, contingent on stockholder approval
- Stockholders approved the amended 2023 Equity Incentive Plan on June 24, 2025, finalizing the grant
- Options represent direct ownership and were granted under the company's Amended 2023 Equity Incentive Plan
- The filing was signed by John Dunn as attorney-in-fact on June 26, 2025
CalciMedica, Inc. (CALC) – Form 4 insider transaction by CFO Stephen Bardin
On 26 June 2025, Chief Financial Officer Stephen Bardin executed two reportable transactions:
- Open-market purchase: 2,000 shares of CALC common stock at a weighted-average price of $1.5025 (price range $1.45-$1.54). The shares are held indirectly by The Bardin Family Trust dated 4 June 2024.
- Employee stock option grant: 20,000 options with an exercise price of $1.53 per share, immediately exercisable and expiring 22 April 2035. The grant was approved by the Board on 23 April 2025 and became effective upon shareholder approval of the amended 2023 Equity Incentive Plan on 24 June 2025.
Post-transaction ownership
- Indirect: 3,000 shares (Bardin Family Trust)
- Direct: 40,000 shares
- Derivative: 20,000 stock options
The filing also corrects a prior Form 4 (3 June 2025) that had misclassified 1,000 trust-held shares as directly owned. No other financial metrics or operational updates were included.
CalciMedica Chief Scientific Officer Kenneth A. Stauderman received a stock option grant for 47,125 shares of common stock on June 24, 2025. The option has an exercise price of $1.53 per share and expires on April 22, 2035.
Key details of the transaction:
- The option grant was initially approved by the Board on April 23, 2025, contingent on stockholder approval
- Stockholders approved the amended 2023 Equity Incentive Plan on June 24, 2025, finalizing the grant
- Options are immediately exercisable upon grant
- This represents a new derivative securities position for the executive
This Form 4 filing indicates ongoing executive compensation alignment through equity incentives, with the exercise price suggesting the company's current market valuation and growth expectations.
Eric W. Roberts, Chief Business Officer, Director, and 10% Owner of CalciMedica, reported receiving a stock option grant for 72,750 shares of common stock. The option grant was initially approved by the Board on April 23, 2025, contingent on stockholder approval of amendments to the company's 2023 Equity Incentive Plan.
Key details of the stock option:
- Exercise price: $1.53 per share
- Grant date: June 24, 2025 (following stockholder approval)
- Expiration date: April 22, 2035
- Immediately exercisable upon grant
- Direct ownership form
The transaction was reported via Form 4 filing, with the document signed by John Dunn as attorney-in-fact on June 26, 2025. This equity compensation grant aligns the executive's interests with those of shareholders through long-term stock ownership potential.
CalciMedica, Inc. (CALC) – Form 4 insider filing
On 24 June 2025, President & COO Michael J. Dunn was granted 47,125 employee stock options with an exercise price of $1.53 per share. The award becomes immediately exercisable and will expire on 22 April 2035.
The option grant had been approved by the Board on 23 April 2025 subject to stockholder approval of amendments to the company’s 2023 Equity Incentive Plan; shareholders ratified the amendment on the same date as the grant (24 June 2025). Following the transaction, Mr. Dunn now beneficially owns 47,125 derivative securities (stock options) directly.
No open-market purchases or sales of common shares were reported, so the filing represents incentive-based compensation rather than a change in Mr. Dunn’s outright share ownership.
Rachel Leheny, Chief Executive Officer, Director, and 10% Owner of CalciMedica (CALC), received a stock option grant for 77,625 shares of common stock on June 24, 2025. The options were granted with the following key terms:
- Exercise price set at $1.53 per share
- Options are immediately exercisable
- Expiration date of April 22, 2035
- Granted under the amended 2023 Equity Incentive Plan
The grant was initially approved by the Board on April 23, 2025, but was contingent on stockholder approval of amendments to the 2023 Equity Incentive Plan, which was obtained on June 24, 2025. This Form 4 filing represents a direct ownership position for Leheny, who serves in multiple leadership roles at the company.
CalciMedica Director Frederic Guerard received multiple stock option grants on June 24, 2025, following stockholder approval of the Amended 2023 Equity Incentive Plan. The grants include:
- 10,000 options at $1.53/share, vesting monthly over one year from March 26, 2025
- 5,000 immediately exercisable options at $1.53/share
- 15,000 options at $1.53/share, vesting monthly over one year from April 1, 2025
- 10,000 options at $1.65/share, vesting monthly over one year from June 24, 2025
All options expire in 2035, with the first three expiring on April 22 and the last on June 23. The final grant will fully vest by the 2026 annual stockholder meeting. Total grant value represents potential rights to purchase 40,000 shares of common stock. These grants were initially approved by the Board on April 23, 2025, contingent on stockholder approval.
CalciMedica, Inc. (CALC) – Form 4 insider filing
Director Alan Glicklich reported the award of four separate stock-option grants on 24 June 2025 under the company’s Amended 2023 Equity Incentive Plan, which was approved by shareholders the same day. All transactions are coded “A” (acquired) and represent incentive compensation rather than open-market buying.
- 10,000 options at an exercise price of $1.53; 1/12th vests monthly over one year from 26 Mar 2025; expires 22 Apr 2035.
- 4,166 options at $1.53; immediately exercisable; expires 22 Apr 2035.
- 15,000 options at $1.53; 1/9th vests monthly over one year from 1 Apr 2025; expires 22 Apr 2035.
- 10,000 options at $1.65; 1/12th vests monthly over one year beginning 24 Jun 2025 (or fully vested by the 2026 AGM); expires 23 Jun 2035.
Following these grants, Glicklich beneficially owns 39,166 derivative securities (options) directly. No common shares were sold or purchased, and no indirect ownership is reported. Because the options are priced near recent market levels and include standard vesting schedules, the filing is primarily routine compensation disclosure with minimal immediate balance-sheet impact but adds modest future dilution potential.
CalciMedica, Inc. (CALC) – Form 4 insider filing dated 26 June 2025
The filing discloses that director Allan Shaw received four separate option grants covering an aggregate 54,844 shares of common stock on 24 June 2025. Three grants, totaling 44,844 options, carry an exercise price of $1.53 and expire on 22 April 2035. A fourth grant of 10,000 options has an exercise price of $1.65 and expires on 23 June 2035.
The awards were approved by the Board on 23 April 2025, but were contingent upon shareholder approval of an amendment to the company’s 2023 Equity Incentive Plan. That amendment was ratified on 24 June 2025, making the options effective the same day.
Vesting schedules are as follows:
- 10,000 options (Grant #1): 1/12 monthly over one year beginning 26 March 2025.
- 8,594 options (Grant #2): fully exercisable immediately.
- 26,250 options (Grant #3): 1/9 monthly over one year beginning 1 April 2025.
- 10,000 options (Grant #4): 1/12 monthly over one year beginning 24 June 2025; fully vested no later than the 2026 annual meeting.
No purchases or sales of already-outstanding common shares were reported, and all securities remain held directly by the reporting person. The filing is a routine incentive-compensation disclosure and does not indicate any change in the director’s ownership of non-derivative equity.
Form 4 highlights for CalciMedica, Inc. (CALC): Director Robert N. Wilson reported the award of four separate stock-option grants on 24 June 2025 following shareholder approval of the amended 2023 Equity Incentive Plan earlier that same day.
Key details: the grants total 68,593 options with exercise prices of $1.53 (three tranches) and $1.65 (one tranche). Vesting schedules differ: (i) 10,000 options vest monthly over 12 months from 26 Mar 2025; (ii) 12,031 options are immediately exercisable; (iii) 36,562 options vest monthly over 12 months from 1 Apr 2025; and (iv) 10,000 options vest monthly over 12 months from 24 Jun 2025 (or fully by the 2026 AGM). All grants expire in April 2035 (first three tranches) or June 2035 (last tranche) and are held directly by the director.
Implications for investors: These are incentive grants—not market purchases or sales—so they do not convey a valuation signal. They do, however, increase the company’s fully diluted share count by roughly 0.6 % (based on ~11 million shares outstanding as of the last 10-Q) and underline ongoing reliance on equity-based compensation. The low strike prices signal CALC’s current trading range and align the director’s upside with shareholders should the share price rise above $1.65 before the 2035 expiry.